Specialty Chemicals Industry: Evonik Q3 Earnings Rise 40%

Evonik Q3 Adjusted EBITDA Rises 40% to €629 Million as Specialty Chemicals Prices Climb

ESSEN, Germany — November 3, 2026 — Evonik Industries AG reported a 40% year-on-year increase in third-quarter adjusted EBITDA to €629 million. The result is a data point for the global specialty chemicals market, where pricing and cost discipline are shaping earnings. The company said full-year operating profit is likely to land in the upper half of its guidance range.

Sales rose 13% from the prior-year quarter, the largest quarterly gain since the third quarter of 2022. Volumes were 2% higher and prices were up 10%. Evonik said the results came despite weak economic growth and geopolitical tensions.

The global specialty chemicals market was valued at USD 563.76 billion in 2023 and is projected to reach USD 762.08 billion by 2030, expanding at a CAGR of 4.4% from 2024 to 2030, according to Next Move Strategy Consulting.

Evonik recorded a net loss of €53 million for the quarter, compared with a €106 million loss a year earlier. The company set aside €313 million for its “Evonik Tailor Made” efficiency program, including severance payments. The program will now run until 2029.

Key Highlights:

• Adjusted EBITDA reached €629 million, up 40%, and the adjusted EBITDA margin rose from 13.2% to 16.4%.

• The Advanced Technologies segment posted an 87% rise in adjusted EBITDA to €377 million, supported by higher volumes, selling prices and optimization programs.

• The Custom Solutions segment recorded a 7% increase in adjusted EBITDA to €231 million.

• Free cash flow in the quarter was €369 million, and it more than doubled to €601 million over the first nine months.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, demand from electronics and pharmaceutical manufacturing continues to underpin the specialty chemicals sector. Raw material price fluctuations remain a key restraint on producers’ cost planning.

NMSC analysts note that Evonik’s quarter reflects the importance of portfolio focus and cost structure in an industry where input costs and end-market demand can shift quickly.

Industry Outlook:

Evonik expects full-year 2026 adjusted EBITDA in the upper half of its €2.0 billion to €2.2 billion range. It also expects fourth-quarter earnings to exceed the same period last year. The company’s medium-term target is a return on capital employed of about 11% by 2029.

The sale process for its Oxeno C4 chemistry business is progressing according to plan, with a buyer expected to be announced in the coming months. Preparations have also begun for a possible sale of Syneqt, the operator of the chemical parks in Marl and Wesseling. Further portfolio and cost measures will be a factor in how specialty chemicals producers manage earnings as conditions evolve.

Source: Evonik Industries AG

For More Information: Download FREE Sample on Specialty Chemicals Market Report

Prepared By: Sanyukta Deb